Mankind Pharma Q3 FY24 Earnings Call Analysis

- **EBITDA Margins**: Targeted to maintain in the range of 24% to 26% for FY'24 and expected to improve with growth in chronic segment and specialty divisions. - **EBITDA Growth**: 39% YoY growth reported in Q3 FY'24, with expectations of further margin expansion driven by chronic portfolio, super specialty divisions, and brand creation. - **Profit After Tax (PAT)**: Robust growth of 55% YoY in Q3 FY'24; future growth expected due to operational efficiencies and strong domestic business. - **Earnings Per Share (EPS)**: Reported diluted EPS of Rs.11.3 for Q3 FY'24; cash EPS at Rs.14.1, indicating healthy earnings quality. - **Expense Growth**: Employee cost increase expected to be controlled, growing at a rate lower than overall company revenue growth. - **Chronic Segment**: Contribution increased from 28% (FY18/19) to 35% currently, with ambitions to reach 40-50% over the medium term, fueling earnings growth. - **Export Business**: Positive double-digit growth expected but not at prior year's exceptional levels. Overall, the company is confident about sustained earnings and margin expansion driven by chronic segment growth, increased MR productivity, and brand leverage.

The transcript provided from the Mankind Pharma Q3 FY24 earnings call does not explicitly mention details about the current or expected order book or pending orders. Key financial and operational highlights discussed include: - Strong revenue growth of 25% in Q3 FY24. - Market share improvements and growth in chronic segment. - Robust growth in modern trade and export business (118% YoY). - Corrective measures taken in consumer healthcare leading to recovery. - Operational efficiencies leading to healthy cash flow and optimized working capital. - Expansion in manufacturing capacity and product launches. No specific data or commentary about order book size or pending orders are disclosed in the transcript sections provided.